I think this message by CTMedic is very much to the point. I certainly feel much better seeing our little stock going up and at 10 than going down at any time, and being way over-invested in such a "flyer" it is noticeable when I look. But I am still confident this is not a flyer anymore, I am hopeful this FDA request for more info is just that and Amarex will jump on it immediately, and the response by buyers thus far is reassuring. I don't think this is a deal-killer for us, and I sure hope Nader and crew get the m2m results out absolutely no later than early next week....And honestly, we wouldn't have the product to sell for both COVID and HIV, so the eye on the ball is definitely on COVID now.

Having said that, I do feel we may be held back a bit with a CEO who has never been through any of this, and is literally learning on the fly. I think this is one reason some of his answers are either off the mark or unclear...he doesn't really know. I'm not certain on the rest of the officers and board members whether they have any such expertise in actually getting a new product through the process, but I should think that would be a very important expertise at this time. I am still very appreciative of what Nader has done in a short time getting Leronlimab to this point with relatively little money, but we are at some very important times for the company, and need to act like it.

I am still long and unwaveringly strong.
To The Moon Alice